Moderate Hepatic Impairment Does Not Affect Doravirine Pharmacokinetics

In VitroResistance Selection with Doravirine (MK-1439), a Novel Nonnucleoside Reverse Transcriptase Inhibitor with Distinct Mutation Development Pathways

(2014) Meizhen Feng et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects

(2014) Matt S Anderson et al.   ANTIVIRAL THERAPY

HCV and HIV co-infection: mechanisms and management

(2014) Jennifer Y. Chen et al.   Nature Reviews Gastroenterology & Hepatology

In VitroCharacterization of MK-1439, a Novel HIV-1 Nonnucleoside Reverse Transcriptase Inhibitor

(2013) Ming-Tain Lai et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Liver Disease in the HIV–Infected Individual

(2010) Jennifer C. Price et al.   Clinical Gastroenterology and Hepatology

Coinfection With HIV-1 and HCV—A One-Two Punch

(2009) Arthur Y. Kim et al.   GASTROENTEROLOGY

Coinfection with Hepatitis C Virus and Human Immunodeficiency Virus: Virological, Immunological, and Clinical Outcomes

(2009) Y. Rotman et al.   JOURNAL OF VIROLOGY

Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction

(2008) Roger K. Verbeeck   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY